Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 301–400 of 1,020
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 124
“In the most recent study conducted by an international research group, Bailey and colleagues, with the use of transcriptomic sequencing, propose 4 molecular subtypes of PDACs: squamous, pancreatic progenitor, aberrantly differentiated endocrine exocrine (ADEX), and immunogenic based on the differential expression of t…”
BackgroundSelf-citationB cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
Mirlekar, B., Michaud, D. E., Lee, S. J., Kren, N. P., Harris, C., Greene, K. G., Goldman, E. C., Gupta, G. P., Fields, R. C., Hawkins, W. G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0349 · Cited by 131
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 127
3D approaches to model the tumor microenvironment of pancreatic cancer
Tomás-Bort, E., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 114
“Yet, a therapeutic breakthrough in pancreatic cancer treatment is still missing [7].”
BackgroundTu, M., Klein, L., Espinet, E., Georgomanolis, T., Wegwitz, F., Li, X., Urbach, L., Danieli‐Mackay, A., Küffer, S., Bojarczuk, K., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00258-w · Cited by 137
Maniati, E., Berlato, C., Gopinathan, G., Heath, O. M., Kotantaki, P., Lakhani, A., McDermott, J. R., Pegrum, C., Delaine‐Smith, R. M., Pearce, O. M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.12.034 · Cited by 116
Self-citationBlasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
Kirby, M. K., Ramaker, R. C., Gertz, J., Davis, N. S., Johnston, B. E., Oliver, P. G., Sexton, K. C., Greeno, E. W., Christein, J. D., Heslin, M. J., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.004 · Cited by 114
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02511 · Cited by 121
“Poor immunogenicity is considered to be one of the causes of poor response to immunotherapies.(13,14) Considering emerging evidence that radiotherapy (RT) may modulate antitumor immune response by promoting danger pattern signals, thereby leading to the recruitment and activation of T cells inside and outside the irra…”
BackgroundSpatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 148
“Tumour spots were further classified as mesenchymal if their mesenchymal signature 18 score in basal genes exceeded the squamous signature 19 score, and conversely, as squamous if the mesenchymal score was lower than the squamous signature score.”
Self-citationLuchini, C., Pea, A., Lionheart, G., Mafficini, A., Nottegar, A., Veronese, N., Chianchiano, P. E., Brosens, L. A. A., Noë, M., Offerhaus, G. J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4941 · Cited by 134
“Several other driver genes are altered at lower prevalence in PDAC [3-6].”
BackgroundSelf-citationMasugi, Y., Abe, T., Ueno, A., Fujii‐Nishimura, Y., Ojima, H., Endo, Y., Fujita, Y., Kitago, M., Shinoda, M., Kitagawa, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0291-z · Cited by 173
Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
Seifert, A. M., Reiche, C., Heiduk, M., Tannert, A., Meinecke, A.-C., Baier, S., von Renesse, J., Kahlert, C., Distler, M., Welsch, T., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1186-7 · Cited by 123
Perkhofer, L., Schmitt, A., Carrasco, M. C. R., Ihle, M., Hampp, S., Ruess, D. A., Heßmann, E., Russell, R., Lechel, A., Azoitei, N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0634 · Cited by 128
“aneuploidy, chromosomal aberrations and copy number changes has been considered as a hallmark of cancer albeit it is not considered as the sole driving force to determine the degree of malignancy (29).”
BackgroundMukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105
Wallez, Y., Dunlop, C. R., Johnson, T. I., Koh, S., Fornari, C., Yates, J. W. T., Fernández, S. B. D. Q., Lau, A., Richards, F. M., & Jodrell, D. I. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0010 · Cited by 130
Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice
Delvecchio, F. R., Fincham, R. E. A., Spear, S., Clear, A. J., Roy-Luzarraga, M., Balkwill, F. R., Gribben, J. G., Bombardieri, M., Hodivala‐Dilke, K., Capasso, M., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.06.023 · Cited by 123
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
Giovannetti, E., van der Borden, C. L., Frampton, A. E., Ali, A., Firuzi, O., & Peters, G. J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.006 · Cited by 126
Koay, E. J., Lee, Y., Cristini, V., Lowengrub, J. S., Kang, Y., Lucas, F. A. S., Hobbs, B. P., Ye, R., Elganainy, D., Almahariq, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3668 · Cited by 110
Self-citationHolokai, L., Chakrabarti, J., Lundy, J., Croagh, D., Adhikary, P., Richards, S. S., Woodson, C., Steele, N., Kuester, R., Scott, A., et al. (2020) · Cancers · doi:10.3390/cancers12123816 · Cited by 110
“clearly demonstrated the predominant expression of profiles related to increased B, CD8+ and regulatory T cell infiltration, and increased acquired tumor immune suppression pathways [37].”
BackgroundStrijker, M., Soer, E. C., Pastena, M. D., Creemers, A., Balduzzi, A., Beagan, J. J., Busch, O. R., van Delden, O. M., Halfwerk, H., van Hooft, J. E., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32586 · Cited by 118
“PDAC shows a very homogeneous mutational landscape with KRAS mutations in approximately 90% of cases, barring the need for extensive coverage and patient-tailored primers.(18,38,39) This implies that ddPCR, which has a lower limit of detection than NGS, would be eminently suited to PDAC.”
BackgroundMekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 137
Arechederra, M., Rullán, M., Amat, I., Oyón, D., Zabalza, L., Elizalde, M., Latasa, M. U., Mercado, M., Ruiz-Clavijo, D., Saldaña, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325178 · Cited by 122
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
“A copy number analysis revealed recurrent gains and losses, implicating genes like MET and CDKN2A [87].”
BackgroundPortrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
Heinrich, M. A., Mostafa, A. M. R. H., Morton, J. P., Hawinkels, L. J. A. C., & Prakash, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.018 · Cited by 126
Self-citationPrognostic value of PDL1 expression in pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Turrini, O., Raoul, J., Delpéro, J., Moutardier, V., Birnbaum, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11685 · Cited by 121
“This was confirmed by the fact that PDL1 mRNA was up-regulated in the squamous subtype vs other subtypes in the Bailey’s data set [42] and in our own data set (data not shown).”
BackgroundInfluentialPoh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets
Qian, H., Zhu, M., Tan, X., Zhang, Y., Liu, X., & Yang, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01775-6 · Cited by 127
“Recent transcriptome pro fi ling has shown that squamous cell lineage markers are present in ~25% of pancreatic ductal adenocarcinoma tumors, and the squamous cell subtype is associated with poorer patient prognosis [12].”
BackgroundVarghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 144
Self-citationTargeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 122
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 116
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 132
Dawkins, J. B. N., Wang, J., Maniati, E., Heward, J. A., Koniali, L., Kocher, H. M., Martin, S. A., Chelala, C., Balkwill, F. R., Fitzgibbon, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0481 · Cited by 111
Moreira, L., Bakir, B. S., Chatterji, P., Dantes, Z., Reichert, M., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.12.004 · Cited by 119
Luo, X., Liu, J., Wang, H., & Lu, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104805 · Cited by 115
Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma
Sperb, N., Tsesmelis, M., & Wirth, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155486 · Cited by 116
“A total of 32 recurrently mutated genes have been identified that aggregate into 10 molecular mechanisms and primarily drive the initiation and progression of the disease [3].”
BackgroundPancreatic cancer subtypes: a roadmap for precision medicine
Torres, C., & Grippo, P. J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1453168 · Cited by 104
“Though the former has been somewhat evasive for pancreatic ductal adenocarcinoma cancer (PDAC), subtyping of this tumour has developed over the past 5 years, culminating in a Nature publication last year that provided genetic signatures for four basic molecular subtypes [1].”
BackgroundStromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
Tanaka, H. Y., & Kano, M. R. (2018) · Cancer Science · doi:10.1111/cas.13630 · Cited by 102
Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
Lomberk, G. A., Dusetti, N., Iovanna, J., & Urrutia, R. A. (2019) · Nature Communications · doi:10.1038/s41467-019-11812-7 · Cited by 113
Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 110
Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer
Li, B., & Wan, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15408 · Cited by 122
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Bärthel, S., Falcomatà, C., Rad, R., Theis, F. J., & Saur, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00526-x · Cited by 120
Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D. N., Chen, W., Enriori, P. J., Ferlin, W. G., Ruwanpura, S. M., & Jenkins, B. J. (2016) · Oncogene · doi:10.1038/onc.2016.437 · Cited by 108
Knudsen, E. S., Balaji, U., Mannakee, B., Vail, P., Eslinger, C., Moxom, C., Mansour, J., & Witkiewicz, A. K. (2018) · Gut · doi:10.1136/gutjnl-2016-313133 · Cited by 101
“The sequencing data are available through dbGaP (PRJNA289986).”
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 111
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L. M., Wirth, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317856 · Cited by 112
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
“, SMAD4, SMAD3, TβR-I, TβR-II, ACVR1B, and ACVR2A), this role is present in 47% of cases [13], highlighting that TGFβ can sometimes acts as a tumor promoter.”
BackgroundKRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01732-6 · Cited by 101
Self-citationShi, X., Li, Y., Yuan, Q., Tang, S., Guo, S., Zhang, Y., He, J., Zhang, X., Han, M., Liu, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29857-6 · Cited by 111
Force-dependent breaching of the basement membrane
Chang, T. T., Thakar, D., & Weaver, V. M. (2017) · Matrix Biology · doi:10.1016/j.matbio.2016.12.005 · Cited by 103
Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer
Mishra, N. K., & Guda, C. (2017) · Oncotarget · doi:10.18632/oncotarget.15993 · Cited by 104
“[73] also proposed a new method for molecular sub-typing of PC using ICGC data.”
Wei, T., Zhang, Q., Li, X., Su, W., Li, G., Ma, T., Gao, S., Lou, J., Que, R., Zheng, L., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1298 · Cited by 105
“We initially focused on the mutations in common driver genes for PDAC including KRAS, TP53, CDKN2A, and SMAD4.”
BackgroundInfluentialPierre-Jean, M., Deleuze, J.-F., Le Floch, E., & Mauger, F. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz138 · Cited by 100
“For instance, it has been used in cancer subtype discovery from gene expression data [19, 41].”
MethodSinkala, M., Mulder, N., & Martin, D. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-58290-2 · Cited by 120
MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma
Maddipati, R., Norgard, R. J., Baslan, T., Rathi, K. S., Zhang, A., Saeid, A., Higashihara, T., Wu, F., Kumar, A., Annamalai, V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1826 · Cited by 97
“222 Human PDAC can be grouped into two main transcriptomic subtypes – a well223 differentiated classical/exocrine-like/progenitor (classical) subtype and a poorly differentiated 224 squamous/quasi-mesenchymal/basal (basal-like) subtype (15,16,18,42).”
Self-citationFalcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 109
Williams, H. L., Costa, A. D., Zhang, J., Raghavan, S., Winter, P. S., Kapner, K. S., Ginebaugh, S. P., Väyrynen, S. A., Väyrynen, J. P., Yuan, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-3050 · Cited by 120
Self-citationPDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance
Roy, N., Takeuchi, K. K., Ruggeri, J. M., Bailey, P., Chang, D., Li, J., Leonhardt, L., Puri, S., Hoffman, M. T., Gao, S., et al. (2016) · Genes & Development · doi:10.1101/gad.291021.116 · Cited by 99
“Consistent with >90% of PDA containing KRAS oncogenic mutations (Bailey et al. 2016), mutant KRAS appears to be responsible for PDA initiation.”
BackgroundMethodInfluentialSelf-citationOrchestration of H3K27 methylation: mechanisms and therapeutic implication
Pan, M., Hsu, M., Chen, L., & Hung, W. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2596-8 · Cited by 118
Synthesis of C4-Aminated Indoles via a Catellani and Retro-Diels–Alder Strategy
Zhang, B., Li, Y., Zhang, Z., An, Y., Wen, Y.-H., Gou, X., Quan, S., Wang, X., & Liang, Y. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b05009 · Cited by 101
Wang, Z., Hausmann, S., Lyu, R., Li, T., Lofgren, S., Flores, N. M., Fuentes, M. E., Caporicci, M., Yang, Z., Meiners, M. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.014 · Cited by 109
“Histopathological analysis was conducted on de-identified slides based on the classification consensus (Bailey et al., 2016).”
MethodSelf-citationTherapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, S. R., Babiker, H. M., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557145 · Cited by 115
“immunotherapy drugs against genomic subtypes of PDAC: pancreatic progenitor, immunogenic, squamous, and aberrantly differentiated endocrine exocrine expression [26].”
BackgroundYu, S.-L., Xu, L.-T., Qi, Q., Geng, Y., Chen, H., Meng, Z.-Q., Wang, P., & Chen, Z. (2017) · Scientific Reports · doi:10.1038/srep45194 · Cited by 127
Hamdan, F. H., & Johnsen, S. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812915116 · Cited by 99
“(8) identified deltaNp63 expression as a hallmark of the squamous subtype, which overlaps with its basal-like counterpart and profoundly correlates with worse prognosis (9).”
BackgroundInfluentialUSP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation
Hou, P., Ma, X., Zhang, Q., Wu, C.-J., Liao, W., Li, J., Wang, H., Zhao, J., Zhou, X., Guan, C., et al. (2019) · Genes & Development · doi:10.1101/gad.326314.119 · Cited by 96
“Genomic profiling of PDAC has provided a comprehensive atlas of recurrent genetic aberrations that may promote PDAC tumorigenesis (Biankin et al. 2012; Waddell et al. 2015; Witkiewicz et al. 2015; Bailey et al. 2016; The Cancer Genome Atlas Research Network 2017).”
BackgroundWinters, I. P., Chiou, S.-H., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 94
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 104
“42 There is a complex relationship between TGF β signalling and either tumour suppression or metastatic spread.”
InfluentialSelf-citationRBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer
Jbara, A., Lin, K., Stossel, C., Siegfried, Z., Shqerat, H., Amar-Schwartz, A., Elyada, E., Mogilevsky, M., Raitses‐Gurevich, M., Johnson, J. L., et al. (2023) · Nature · doi:10.1038/s41586-023-05820-3 · Cited by 101
A developmental constraint model of cancer cell states and tumor heterogeneity
Patel, A. S., & Yanai, I. (2024) · Cell · doi:10.1016/j.cell.2024.04.032 · Cited by 105
Mishra, V. K., Wegwitz, F., Kosinsky, R. L., Sen, M., Baumgartner, R., Wulff, T., Siveke, J. T., Schildhaus, H.-U., Najafova, Z., Kari, V., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx212 · Cited by 95
The glycosylation landscape of pancreatic cancer (Review)
Munkley, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.9885 · Cited by 96
“Recent profiling has defined 4 molecular subtypes of pancreatic cancer (94), and it likely that diversity exists between pancreatic cancers in the variety and type of glycans made and secreted into the blood (24).”
BackgroundStroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Jiang, B., Zhou, L., Lu, J., Wang, Y., Liu, C., You, L., & Guo, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576399 · Cited by 93
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Luna, J., Boni, J., Cuatrecasas, M., Ros, X. B., Núñez-Manchón, E., Gironella, M., Vaquero, E. C., Arbonés, M. L., de la Luna, S., & Fillat, C. (2018) · Gut · doi:10.1136/gutjnl-2018-316128 · Cited by 97
Jiang, Z., Liang, G., Xiao, Y., Qin, T., Chen, X., Wu, E., Ma, Q., & Zheng, W. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919855238 · Cited by 104
Tang, R., Zhang, Y., Liang, C., Xu, J., Meng, Q., Hua, J., Liu, J., Zhang, B., Yu, X., & Shi, S. (2020) · PeerJ · doi:10.7717/peerj.9602 · Cited by 115
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 111
“Bailey et al. defined a 4-subtype classification based on genomic expression analysis, including squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX) [32].”
BackgroundLeiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 135
“6 The global trend in the incidence of pancreatic cancer from 2022 to 2050, both sexes, all ages, based on continents Among these subtypes, the pancreatic progenitor sub-type had the best survival outcomes, while the squamous subtype demonstrated the worst outcomes [47, 48].”
InfluentialImpact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
“ARID1A[20] RNF43 [ 19] ATM [ 16] KMT2C [ 16] KMT2D [ 15] RB1 [ 15] GNAS [ 13] KDM6A [ 11] BRCA2 [ 7] FLCN [ 7] APC [ 6] PALB2 [ 6] SMARCA4 [ 6] ARID1B [ 5] BCOR [ 5] LRP1B [ 5] NF1[ 5] PTEN [ 5] U2AF1 [ 5] AMER1 [ 4] In summary, we reported the KRAS mutation allele-speci fi c clinical outcomes in…”
Self-citationWitkiewicz, A. K., Balaji, U., Eslinger, C., McMillan, E., Conway, W., Posner, B., Mills, G. B., O’Reilly, E. M., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.023 · Cited by 93
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
Ansari, D., Bauden, M. P., Bergström, S., Rylance, R., Marko‐Varga, G., & Andersson, R. E. (2017) · British journal of surgery · doi:10.1002/bjs.10471 · Cited by 98
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 93
“In a subsequent study by Bailey and colleagues based on unsupervised clustering of RNA sequencing (RNA-seq) data, four subtypes were distinguished (9).”
BackgroundInfluentialRecent advances in understanding the complexities of metastasis
Chitty, J. L., Filipe, E. C., Lucas, M. C., Herrmann, D., Cox, T. R., & Timpson, P. (2018) · F1000Research · doi:10.12688/f1000research.15064.1 · Cited by 93
Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
Birnbaum, D. J., Bertucci, F., Finetti, P., Birnbaum, D., & Mamessier, É. (2019) · Cancers · doi:10.3390/cancers11040497 · Cited by 103
“The Bailey’s classification identified the four subtypes: ADEX (21%), immunogenic (18%), pancreatic progenitor (22%), and squamous (39%).”
MethodInfluentialNicolle, R., Blum, Y., Duconseil, P., Vanbrugghe, C., Brandone, N., Poizat, F., Roques, J., Bigonnet, M., Gayet, O., Rubis, M., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102858 · Cited by 93
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 96
Raufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 110
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 121
Melisi, D., García‐Carbonero, R., Macarulla, T. M., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Kozloff, M. F., Simionato, F., Cleverly, A., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03807-4 · Cited by 100
New therapeutic targets in pancreatic cancer
Lai, E., Puzzoni, M., Ziranu, P., Pretta, A., Impera, V., Mariani, S., Liscia, N., Soro, P., Musio, F., Persano, M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101926 · Cited by 100
“suggested the existence of four molecular subtypes with different biological features and prognostic relevance: squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX) (the last two as subclasses of the pancreatic progenitor subtype)[16].”
BackgroundYuan, S., Natesan, R., Rivera, F. J. S., Li, J., Bhanu, N. V., Yamazoe, T., Lin, J., Merrell, A. J., Sela, Y., Thomas, S. K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1299 · Cited by 98
“Briefly, the top 500 and bottom 500 protein-coding genes of each subtype were identified from RNA-seq data derived from patient samples (31), and used to define each subtype’s gene signature.”
MethodZhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00066-3 · Cited by 97
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Yi, M., Tan, Y., Wang, L., Cai, J., Li, X., Zeng, Z., Xiong, W., Li, X., Li, X., Tan, P., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03539-2 · Cited by 96
Kimura, Y., Fukuda, A., Ogawa, S., Maruno, T., Takada, Y., Tsuda, M., Hiramatsu, Y., Araki, O., Nagao, M., Yoshikawa, T., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.039 · Cited by 90
Gene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 94
“Using a RNAseq based expression analysis of 100 tumors; four classes of PDAC were identified, including a “pancreatic progenitor subtype”.(79) This subtype contained subclasses with active transcriptional networks characteristic of late stages of pancreas development termed Abnormally Differentiated Endocrine and eXoc…”
Self-citationKloesch, B., Ionasz, V. S., Paliwal, S., Hruschka, N., de Villarreal, J. M., Öllinger, R., Mueller, S., Dienes, H. P., Schindl, M., Gruber, E. S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321397 · Cited by 96
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.